Autopsy report · NCT00285415

A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation

“Investigator abruptly left Carilion.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 10 months after it had already started.
• Ran for about 7 years 2 months before it stopped.
• 46 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Carilion Clinic

Sponsor type

University, hospital or other

Conditions

Advanced Endometrial Adenocarcinoma, Stage III A, B, C

Interventions

Docetaxel and Carboplatin

Participants

46

Sites

2

Countries

United States

Trials that died the same way

• Fast Track for Wrist and Scaphoid Fractures
  “Investigator's departure” (62% match in meaning)
• Study on the Efficacy of Infiltration of Upper Cluneal Nerves in Chronic Pain Related to Cluneal Syndrome
  “Investigator left the team” (61% match in meaning)
• Intralesional Tetracycline Injection in the Treatment of Chalazia
  “Investigator left the institution” (60% match in meaning)
• Links Between Perception of Temporal Order Judgment and Causality in Schizophrenia
  “Investigator departure” (60% match in meaning)
• Direct Stimulation Of Spinal Nerve Roots To Determine Sensory And Motor Innervation Patterns
  “One of the investigators left the Institution” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.